Rubbish Check
CNBC Top News · 13 October 2026
source“J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027”
R4/ 10
Selective
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates CNBC's headline that J&J "beats earnings estimates" a 4/10 because the top-line beat was real, but the headline omits that shares fell 2% and that the MedTech and Darzalex divisions both missed estimates.
The Verdict
Selective. The headline isn't false, revenue and adjusted EPS did beat consensus, and the mid-2027 spinoff timeline is accurately sourced to the CFO. But stacking "beats earnings estimates" next to a forward-looking growth story (the spinoff) while leaving out that the stock dropped and that MedTech and Darzalex missed creates a rosier picture than the quarter actually supports.
What actually happened
Johnson & Johnson reported third-quarter revenue and adjusted earnings per share above Wall Street's consensus, lifted mainly by strong Tremfya sales, and confirmed it is targeting mid-2027 to spin off its DePuy Synthes orthopedics unit. The company also nudged up its full-year sales and EPS guidance. Despite the beat, shares fell 2% in pre-market trading, and management flagged that Middle East conflict, European austerity, and China pricing pressure were weighing on international results more heavily than before.
Key facts
- Q3 revenue: $25.4B vs. analyst estimate of $25.28B (beat)
- Adjusted EPS: $2.59 vs. estimate of $2.54 (beat)
- Tremfya sales: up 68% to $2.4B, beating the ~$2.19B estimate
- Stelara sales: down 54% to $716M on generic competition, but still above the $591M estimate
- Darzalex sales: up ~16% to $4.24B, short of the $4.4B estimate
- MedTech sales: up only 2.5% to $8.6B, missing the $8.71B estimate (cardio and surgery drove the miss, per J.P. Morgan's Chris Schott)
- Shares fell 2% before the bell on the day of the report, despite being up 27% year-to-date
- Full-year sales guidance raised modestly: midpoint to ~$101.2B from $101.1B; EPS midpoint to $11.10 from $11.04
- DePuy Synthes spinoff targeted for "sometime next year" (mid-2027), with Apollo Global Management reportedly in talks to acquire the unit for close to $20B (per Bloomberg, September)
What to watch for
- Whether the Apollo talks for DePuy Synthes actually close near the reported $20B valuation, or whether CFO Joe Wolk's "we're not cash strapped" comment signals J&J will walk from a lowball offer.
- Continued MedTech softness, especially in cardio/surgery and the Abiomed heart pump line, which has been dragged by a UK study questioning Impella use in high-risk procedures.
- Whether Middle East, Europe, and China headwinds "in a more pronounced way" deepen next quarter, since management explicitly flagged this as a trend to watch rather than a one-off.
About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
